🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Allogene Therapeutics, Inc. ALLO R2KR3KPHARMA

Healthcare · Biotechnology · United States
Financial distress score 54/100 (Weak) — see indicators →
https://allogene.com
Company Profile ↓
$1.25
+20.19% 1Y
Mkt Cap$431.86M
P/E-1.89
P/B1.16
52W High$3.06
52W Low$1.04
Book Value$1.26
EPS (TTM)$-0.66

Company Overview

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.18.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:+20.19%
6 Months:-45.89%
3 Months:-28.57%
1 Month:-25.15%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 10% of range
$1.04 $3.06
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)25.99 · Oversold
Price Performance
1M-25.15%
3M-28.57%
6M-45.89%
1Y+20.19%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 59.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.89
Industry PE
25.45
Forward P/E
-2.03
PEG Ratio
-
Book Value
$1.26
Price to Book
1.16
P/S
108.71
EV/EBITDA
-1.43
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-53.97%
ROE
-42.39%
ROA
-22.08%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.18
EPS (TTM)
$-0.66

Balance Sheet & Liquidity

Debt/Equity
0.18
Quick Ratio
10.55
Current Ratio
10.72
Debt
$79.01M
Total Assets
$395.96M
Current Assets
$273.29M
Working Capital
$225.24M

Ownership

Promoter Holding
11.03%
Chg in Prom Hold
-0.01%
FII / Inst Holding
82.62%
Chg in FII Hold
-5.38%

Financial Snapshot

Enterprise Value
$431.86M
Total Revenue (TTM)
$4.64M
EBITDA
$-168.65M
Free Cash Flow
$-63.46M
Operating Cash Flow
$-102.20M
Shares Outstanding
345.49M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALLO Allogene Therapeutics, Inc. R2KR3KPHARMA 1.25 -1.89 $431.86M 0.00% -53.97% -42.39% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------00038.34M44.00K49.00K39.00K64.00K27.00K30.00K22.00K22.00K22.00K0--00000
Cost of Revenue -----------------------------
Gross Profit -----------------------------
Operating Expenses ------------------------65.19M54.44M44.90M42.40M46.09M
Operating Income -2.60M-135.01M-22.19M-33.05M-36.46M-45.96M-55.01M-64.58M-57.68M-63.16M-68.04M-33.20M-71.03M-77.67M-80.01M-76.62M-82.51M-99.09M-80.54M-63.00M-69.50M-71.43M---65.19M-54.44M-44.90M-42.40M-46.09M
EBITDA -------------------------56.48M-47.57M-37.96M-35.44M-39.44M
Interest Expense ------------------------150.00K268.00K344.00K313.00K300.00K
Pretax Income -------------------------59.73M-50.94M-41.40M-38.81M-42.61M
Tax Provision -----------------------------
Net Income -2.60M-134.90M-43.50M-30.51M-31.59M-41.24M-50.73M-61.03M-54.48M-60.97M-66.20M-33.02M-70.94M-78.19M-78.61M-80.29M-84.24M-99.97M-79.23M-62.29M-65.00M-66.36M---59.73M-50.94M-41.40M-38.81M-42.61M
Diluted EPS ----------0.53-0.52-0.25-0.53-0.57-0.56-0.56-0.59-0.69-0.54-0.37-0.38-0.35---0.28-0.23-0.19-0.17-0.18
R&D Expense -122.49M10.87M-23.40M31.77M39.99M-42.04M47.30M51.42M55.18M52.29M58.72M60.16M57.17M63.64M80.24M62.04M45.98M52.26M50.35M44.71M-50.20M40.16M31.16M-32.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -00-156.00K95.00K22.00K0
Cost of Revenue --------
Gross Profit --------
Operating Expenses ----335.69M314.59M257.50M206.93M
Operating Income -192.84M-202.01M-258.24M--335.54M-314.49M-257.48M-206.93M
EBITDA -----321.24M-313.07M-243.33M-177.45M
Interest Expense -----0181.00K1.07M
Pretax Income -----340.41M-327.26M-257.15M-190.89M
Tax Provision ---0-0443.00K0
Net Income -211.50M-184.59M-250.22M--340.41M-327.26M-257.59M-190.89M
Diluted EPS --1.83-2.08--2.32-2.09-1.32-0.87
R&D Expense 151.86M144.53M192.99M220.18M256.39M242.91M192.30M150.15M

Balance Sheet (Annual)

Figures in USD.

Metric Nov 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Dec 2024Dec 2025
Total Assets --773.86M717.80M1.23B-978.09M955.62M894.48M821.58M750.13M773.01M713.41M642.84M548.71M415.90M
Current Assets ---------528.82M---459.12M303.39M257.75M
Cash & Equivalents --92.43M175.13M183.35M-84.51M96.04M74.36M61.90M109.93M154.76M69.25M83.16M75.22M51.69M
Inventory ----------------
Receivables ----------------
Total Liabilities -2.00K70.69M88.78M148.21M-112.82M149.14M151.08M154.70M158.12M151.60M132.78M130.60M126.53M123.36M
Current Liabilities -2.00K29.46M33.08M94.32M-36.62M44.18M48.08M53.73M59.40M54.58M37.49M37.08M35.52M32.51M
Long Term Debt ----------------
Total Debt ---------101.12M---95.12M90.76M83.25M
Total Equity 0-2.00K703.16M629.02M1.01B-865.27M806.48M743.40M666.88M592.01M621.41M580.63M512.23M422.18M292.54M
Shares Outstanding ---------144.44M---168.64M212.21M229.41M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -44.65M-137.35M-115.09M--220.52M-237.73M-200.30M-149.25M
Investing Cash Flow -632.80M164.08M-505.12M-106.16M163.29M75.69M95.56M
Financing Cash Flow 771.18M58.96M633.59M-2.95M95.69M116.67M30.16M
Capital Expenditure -3.23M-50.79M-65.96M--5.19M-1.52M-694.00K-386.00K
Free Cash Flow -47.89M-188.14M-181.05M--225.71M-239.25M-200.99M-149.63M
Net Change in Cash -----111.41M21.25M-7.94M-23.53M

Ratios (Annual)

Figures in %.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------
Operating Margin % -----215,087.2%-331,044.2%-1,170,372.7%-
Net Margin % -----218,214.1%-344,489.5%-1,170,863.6%-
ROE % -30.1%-29.3%-24.7%--51.0%-63.9%-61.0%-65.3%
ROCE % -25.9%-29.5%-22.8%--43.7%-51.9%-50.2%-54.0%

Shareholding Pattern

Insiders
11.03%
Institutions
82.62%
Public Float
92.86%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.73% 30.15M $44.01M
2 Frazier Life Sciences Management, L.P. 6.50% 22.45M $32.77M
3 Pfizer Inc 6.38% 22.03M $32.17M
4 State Street Corporation 5.51% 19.03M $27.78M
5 TPG GP A, LLC 5.42% 18.72M $27.33M
6 Sio Capital Management, LLC 3.86% 13.32M $19.45M
7 Primecap Management Company 3.80% 13.12M $19.16M
8 Vanguard Capital Management LLC 3.52% 12.17M $17.76M
9 FMR, LLC 3.48% 12.01M $17.53M
10 Citadel Advisors Llc 2.92% 10.09M $14.73M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALLO

Yahoo Finance Wed, 02 Sep 2026

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune…

Yahoo Finance Mon, 31 Aug 2026

Allogene Therapeutics Announces Participation in September Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune …

Yahoo Finance Wed, 19 Aug 2026

Allogene (ALLO) Q2 2026 Earnings Call Transcript

Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations.

Yahoo Finance hu, 13 Aug 2026

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Yahoo Finance hu, 13 Aug 2026

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

Allogene Therapeutics (ALLO) remains attractive given its undemanding valuation and differentiated c

Yahoo Finance hu, 13 Aug 2026

Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ...

Allogene Therapeutics Inc (ALLO) advances its allogeneic CAR-T pipeline with key regulatory milestones and strong trial momentum, while navigating solid tumor challenges and competitive pressures.

ALLO — Frequently Asked Questions

What is the current share price of Allogene Therapeutics, Inc. (ALLO)?

As of 2026-10-23 16:27 PDT, Allogene Therapeutics, Inc. (ALLO) trades at $1.25 on NasdaqGS. Its 52-week range is $1.04 to $3.06.

What is the market capitalisation of ALLO?

Allogene Therapeutics, Inc. (ALLO) has a market capitalisation of $431.86M on NasdaqGS.

What is the P/E ratio of ALLO?

ALLO trades at a trailing price-to-earnings (P/E) ratio of -1.89. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.16.

What is the return on equity (ROE) of ALLO?

ALLO has a return on equity (ROE) of -42.39%. Its return on capital employed (ROCE) is -53.97%.

Is ALLO a good stock to buy?

This page provides a data-driven analysis of Allogene Therapeutics, Inc. (ALLO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space